Accordingly, Chen et al. reported that metastatic melanoma releases high levels of PD-L1 positive-EVs and that the level of circulating exosomal PD-L1 changes during the course of anti-PD-1 therapy (Chen et al., 2018). Here, PDCD1 is linked to metastatic melanoma.